Phoenix PharmaLabs Celebrates Successful Netcapital Equity Offering for Non-Addictive Opioid Pain Treatment

Phoenix PharmaLabs, Inc., a private company developing what is reportedly the world’s first non-addictive opioid for treatment of moderate to severe pain, recently celebrated a successful equity offering of more than $1.1 million via Netcapital, an SEC-approved equity funding portal. A combination of accredited and non-accredited investors participated in the offering, which commenced 11 October 2018 and closed 30 March 2019.

“This very positive response to our offering, coupled with a $2.7 million grant awarded by the US Army last year, enables Phoenix to accelerate completion of our preclinical studies and scale-up of manufacturing of PPL-103,” indicated Phoenix PharmaLabs President and CEO William Crossman. “As a result, we anticipate filing an Investigational Drug Application (IND) with the FDA within approximately 15 months. When approved it will enable us to enter Phase I human clinical trials.”

Phoenix PharmaLabs is a preclinical drug discovery company focused on the development and commercialization of new potent, non-addictive treatments for pain and new therapies for the treatment of addiction. Crossman anticipates commencing Non-Human Primate (NHP) studies (which will include efficacy studies as well as further studies of abuse/addiction potential).

. @PhoenixPharmLB!! Phoenix PharmaLabs targets opioid crisis by developing a potent, safe, non-addictive painkiller. $1.1 million raised @netcapital @jfrishman37 Click to Tweet

According to the biotech company, earlier in vivo studies “have all indicated that PPL-103 performs exceptionally well and appears to be safe and non-addicting, with none of the side effects normally associated with opioids.” Previous self-administration studies in rats have demonstrated that PPL-103 is non-addictive and those studies correlate very closely to equivalent studies in humans.

“The success of Phoenix PharmaLabs’ offering demonstrates the significant interest among the investing public in finding solutions to real world problems, such as combating the opioid crisis,” observed Jackson Stone, Netcapital Director of Business Development. “Many Phoenix investors included physicians, nurses and pharmacists who appear to understand the pharmacological need for safe, non-addictive analgesics as well as individuals who have personally been affected by the devastation of the opioid crisis. Phoenix is the first offering on the Netcapital portal to fully max out their yearly Section 4(a)(6) allocation of $1.07M to non-accredited investors, which further illustrates the phenomenal success of the Phoenix asset and team in this offering.”

Phoenix PharmaLabs, Inc. noted that PPL-103, a partial-agonist targeting all three pain receptors in the brain (mu, kappa and delta), has been under development for more than a decade, and that all opioids on the market today bind to the mu receptor in the brain and then aggressively stimulate that receptor. The mu receptor produces euphoria that leads to abuse and addiction. PPL-103 is an analog that binds strongly to all three opioid receptors in the brain and then just partially stimulates each of those receptors in a more balanced manner. This partial simulation derives potent analgesic benefit from all three receptors but is not sufficiently strong to produce the serious opioid side-effects associated with any single receptor. This results in the first-ever opiate analgesic that appears to be non-addicting and free of all dangerous side effects.

Phoenix PharmaLabs, Inc. cited published and unpublished in vivo studies showing how the PPL-103 efficacy of has been demonstrated to be:

  • An orally active potent pain killer (10x more potent than morphine)
  • Does not cause death from overdose (even when given 350x the analgesic dose)
  • Does not cause physical dependence or withdrawal
  • Does not cause constipation (even at 100x dose)
  • Has demonstrated potential as an opioid addiction therapy drug that could replace currently used treatments that are themselves addictive opioids.
  • Has demonstrated in early trials the potential as a treatment for cocaine addiction.

For more detailed Phoenix PharmaLabs, Inc. campaign information, please click here. Current live campaigns Charles & Company is an organic luxury tea brand, Braidy Industries, Flagship Fitness, Ghost Tequila and PropertyClub.


Have a crowdfunding offering you'd like to share? Submit an offering for consideration using our Submit a Tip form and we may share it on our site!

Sponsored Links by DQ Promote

Send this to a friend